购物车
- 全部删除
- 您的购物车当前为空
Ciglitazone (ADD 3878) 是一种强效和选择性的PPARγ激动剂(EC50:3μM)和口服降糖药。Ciglitazone 抑制th17细胞的增殖和分化,降低胰岛素水平、血管内皮生长因子的产生和血压,诱导胃癌细胞的细胞周期停止。Ciglitazone 能诱导负鼠肾上皮细胞的凋亡,激活p38 MAPK 和凋亡诱导因子(AIF)的核转位。 Ciglitazone 在肥胖症和高血糖症的动物模型中表现出降血糖活性。
Ciglitazone (ADD 3878) 是一种强效和选择性的PPARγ激动剂(EC50:3μM)和口服降糖药。Ciglitazone 抑制th17细胞的增殖和分化,降低胰岛素水平、血管内皮生长因子的产生和血压,诱导胃癌细胞的细胞周期停止。Ciglitazone 能诱导负鼠肾上皮细胞的凋亡,激活p38 MAPK 和凋亡诱导因子(AIF)的核转位。 Ciglitazone 在肥胖症和高血糖症的动物模型中表现出降血糖活性。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | ¥ 746 | 现货 |
产品描述 | Ciglitazone (ADD 3878) is a potent and selective PPARγ agonist (EC50: 3 μM) and oral hypoglycemic agent. Ciglitazone inhibits proliferation and differentiation of th17 cells, decreases insulin levels, vascular endothelial growth factor production and blood pressure, and induces cell cycle arrest in gastric cancer cells. Selegiline induces apoptosis in opossum kidney epithelial cells and activates nuclear translocation of p38 MAPK and apoptosis-inducing factor (AIF). Ciglitazone exhibits hypoglycaemic activity in animal models of obesity and hyperglycaemia. |
靶点活性 | PPARγ:3 μM(EC50) |
体外活性 | Ciglitazone(0-20 μM;24小时)通过PPAR独立机制,导致ROS的产生、细胞内Ca2+水平的增加,并诱导凋亡。[4] |
体内活性 | Ciglitazone(100 mg/kg/天;2天;C57BL/6J-ob/ob小鼠)显著降低血糖水平。[3] 同时,在给予Ciglitazone(100 mg/kg/天;41-44天;ob/ob小鼠)后,观察到胰岛β细胞脱颗粒化和胰岛素含量增加。[3] |
别名 | 环格列酮, U-63287, U 63287, Ciglitazona, ADD-3878, ADD3878, ADD 3878 |
分子量 | 333.45 |
分子式 | C18H23NO3S |
CAS No. | 74772-77-3 |
Smiles | CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1 |
密度 | 1.189 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 90.0 mg/mL (269.9 mM ), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容